New USP Draft Chapter <1168> Compounding for Phase I Investigational Studies
![GMP meets Development](files/eca/userImages/training.img/Z-ECA-GMP-meets-Development.jpg)
Recommendation
5-7 November 2024
Hamburg, Germany
GMP and FDA Compliance in Pharmaceutical Development and IMP Manufacturing
The USP Compounding Expert Committee republished a draft of a new General Chapter <1168> Compounding for Phase I Investigational Studies for public comment. The chapter was previously published in Pharmacopeial Forum 39(5) [Sep.-Oct. 2013] for public comment and has been revised based on stakeholder input received.
The USP posted its Notice of Intent to Revise online together with a PDF of the current proposed chapter containing line numbers on April 28, 2017. Additionally, the draft chapter has been published in Pharmacopeial Forum (PF) 43(3) [May–June 2017]. The comment deadline is July 31, 2017.
Due to the complexity of the drug development process, the pharmaceutical industry applies various tools to improve efficiency. One of these tools is the use of compounding to supply investigational preparations for Phase I clinical studies. The USP says that the "General Chapter <1168> was developed to provide guidance on compounding for investigational preparations for Phase I clinical studies. Compounding of investigational preparations requires additional considerations because it is likely that the agents in these preparations have never been administered to humans."
Major changes from the previous chapter published in PF 39(5) include:
- Clarification of information that a compounder should know as part of participating in a study involving the compounding of investigational preparations;
- Clarification of personnel responsibilities on materials management.
Additionally, minor editorial changes have been made to update this chapter to current USP style.
The structure of the proposed chapter is as follows:
1. INTRODUCTION
1.1 Scope
1.2 Background
1.3 Applicable Regulatory Requirements
1.4 Best Practices
2. PERSONNEL TRAINING
3. BUILDINGS AND FACILITIES
4. EQUIPMENT AND COMPONENTS
4.1 Equipment
4.2 Components
5. STANDARD OPERATING PROCEDURES
6. PREPARATION ACTIVITIES
6.1 Retention Samples
6.2 Disposition of Unused Materials and Preparations
7. RELEASE OF INVESTIGATIONAL AGENT/PREPARATION
8. LABELING
9. ESTABLISHING BEYOND-USE DATES
10. QUALITY ASSURANCE AND QUALITY CONTROL
11. STORAGE, HANDLING, PACKAGING, AND TRANSPORT
11.1 Storage
11.2 Handling
11.3 Packaging
11.4 Transport
12. DOCUMENTATION
12.1 Safety Data Sheets
12.2 Certificate of Analysis
12.3 Records Management
APPENDIX
The complete draft chapter can be found on the USP Notices website. Comments can be submitted by using the electronic form Public Comments on Proposed USP General Chapter <1168>.
Related GMP News
23.07.2024Pilot Results on Regulatory-Led RWE Generation
23.07.2024ICH M12 Guideline on Drug Interaction Studies
20.06.2024Draft ICH M14 Guideline on Real-World Data for Safety Assessment
20.06.2024Glossary of Terms and Definitions for Innovative Clinical Trials
21.05.2024Real-World Evidence: FDA´s Considerations for Non-Interventional Studies
14.05.2024How to Handle and Reserve Samples from BA / BE Studies